表柔比星方案辅助化疗治疗乳腺癌的剂量选择

Selection of Therapeutic Dose of Adjuvant Chemotherapy for Breast Cancer

目的研究分析不同剂量表柔比星化疗方案对乳腺癌患者的疗效。方法将乳腺癌患者252例纳为研究对象,随机分为观察组(126例)与对照组(126例)。予观察组以大剂量表柔比星,对照组以小剂量表柔比星,余予相同剂量多西他赛、环磷酰胺。经3个疗程化疗后,统计分析两组患者近期缓解情况、生存率、不良反应以及不同剂量表柔比星化疗方案在不同因素下对患者无病生存期的影响。结果经3个疗程的化疗后两组患者中病情缓解、病情稳定、病情进展的比例无显著差异(P> 0. 05),两组1、3、5年生存率比较,无明显差异(P> 0. 05)。而观察组患者发生血液系统不良反应、消化系统不良反应的比例高于对照组(P <0. 05),观察组中三阴性及ER/PR阴性乳腺癌患者的平均无病生存期高于对照组(P <0. 05)。结论表柔比星剂量的大小对乳腺癌患者的近期缓解率及5年生存率无明显影响,大剂量表柔比星化疗方案的血液系统副反应、消化系统副反应大于小剂量表柔比星,而大剂量表柔比星对三阴性及ER/PR阴性乳腺癌患者有显著的疗效。

Objective To study the efficacy of different doses of rebovacin chemotherapy in breast cancer patients.Methods A total of 252 patients with breast cancer were included in the study and were randomly divided into observation group(126 cases)and control group(126 cases).The observation group was given a large dose of epirubicin,and the control group was given a small dose of epirubicin,and the same dose of docetaxel or cyclophosphamide was given.After 3 courses of chemotherapy,the short-term remission,survival rate,adverse reactions and the effects of different doses of epirubicin chemotherapy on the disease-free survival of patients were analyzed statistically.Results After 3 courses of chemotherapy,there was no significant difference in the degree of remission,stable disease,and progression of the disease between the two groups(P >0.05).There was no significant difference in the 1,3 and 5 year survival rates between the two groups(P >0.05).The proportion of adverse reactions in the blood system and adverse reactions of the digestive system in the observation group was higher than that in the control group(P<0.05).The average disease-free survival of the patients with triple-negative and ER/PR-negative breast cancer in the observation group was higher than that of the control group(P<0.05).Conclusion The dose of epirubicin has no significant effect on the short-term remission rate and 5-year survival rate of breast cancer patients.The blood system side reaction and digestive system side reaction of high-dose epirubicin chemotherapy regimen are greater than the small dose softness ratio.Star,while high-dose epirubicin has a significant effect on patients with triple-negative and ER/PR-negative breast cancer.